August 28, 2015
1 min read

Probiotic ineffective for prevention, elimination of GI colonization with drug-resistant organisms

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

Administration of probiotics showed no benefit or harm for preventing or eliminating gastrointestinal colonization with multidrug-resistant organisms in ICU patients, according to results from a randomized controlled trial.

“Our research suggests that probiotics do not help prevent gastrointestinal colonization with multidrug-resistant organisms in critically ill patients,” Jennie H. Kwon, DO, from the division of infectious diseases at Washington University School of Medicine in St. Louis, said in a press release.

Aiming to determine whether Lactobacillus rhamnosus GG can safely prevent intestinal colonization with multidrug-resistant organisms in critically ill patients, Kwon and colleagues performed a prospective, randomized controlled pilot study at Barnes-Jewish Hospital from February 2012 to October 2013. They randomly assigned 103 adult ICU patients to standard of care or one probiotic capsule containing 1 x 1010 L. rhamnosus GG cells (Culturelle, i-Health) twice daily for 2 weeks or until study exit. Patients with intubation or nasogastric tube received the probiotic via a saline slurry.

The primary outcome was colonization of multidrug-resistant organisms in the GI tract, including Clostridium difficile, vancomycin-resistant enterococci and Pseudomonas aeruginosa, and secondary endpoints were safety and loss of colonization. Stool or rectal swab samples were collected at enrollment and every 3 days, and 70 patients with at least three specimens were included in the outcomes analysis.

They found no difference in acquisition of any multidrug-resistant organisms between the probiotic group (10%) and patients who received standard of care (15%). There also was no difference in loss of colonization between groups, and no probiotic-related adverse events.

The researchers acknowledged the study’s limitations include small sample size, length of follow-up, use of a single probiotic type and dose, extensive exclusion criteria and that they “did not survey for gastric or upper airway colonization, which may be an important site for [multidrug-resistant organism] colonization.”

“Further research is needed on this emerging intervention to evaluate the effectiveness in preventing intestinal colonization of drug-resistant organisms,” Kwon said in the press release. – by Adam Leitenberger

Disclosure: Kwon reports no relevant financial disclosures. Please see the study for a full list of all other researchers’ relevant financial disclosures.